Gupta Akanksha, Berg David T, Gerlitz Bruce, Richardson Mark A, Galbreath Elizabeth, Syed Samreen, Sharma Avadhesh C, Lowry Stephen F, Grinnell Brian W
Division of Biotechnology Discovery Research, Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, Indiana 46285-0444, USA.
Shock. 2007 Oct;28(4):468-76. doi: 10.1097/SHK.0b013e3180487f09.
Activated protein C (APC) is an important modulator of vascular function that has antithrombotic and anti-inflammatory properties. Studies in humans have shown modulation of endotoxin-induced hypotension by recombinant human APC, drotrecogin alfa (activated), however, the mechanism for this effect is unclear. We have found that APC suppresses the induction of the potent vasoactive peptide adrenomedullin (ADM) and could downregulate lipopolysaccharide (LPS)-induced ADM messenger RNA (mRNA) and nitrite levels in cell culture. This effect was dependent on signaling through protease-activated receptor 1. Addition of 1400W, an irreversible inducible nitric oxide synthase (iNOS) inhibitor, inhibited LPS-induced ADM mRNA, suggesting that ADM induction is NO mediated. Furthermore, in a rat model of endotoxemia, APC (100 microg/kg, i.v.) prevented LPS (10 mg/kg, i.v.)-induced hypotension, and suppressed ADM mRNA and protein expression. APC also inhibited iNOS mRNA and protein levels along with reduction in NO by-products (NOx). We also observed a significant reduction in iNOS-positive leukocytes adhering to vascular endothelium after APC treatment. Moreover, we found that APC inhibited the expression of interferon-gamma (IFN-gamma), a potent activator of iNOS. In a human study of LPS-induced hypotension, APC reduced the upregulation of plasma ADM levels, coincident with protection against the hypotensive response. Overall, we demonstrate that APC blocks the induction of ADM, likely mediated by IFN-gamma and iNOS, and suggests a mechanism that may account for ameliorating LPS-induced hypotension. Furthermore, our data provide a new understanding for the role of APC in modulating vascular response to insult.
活化蛋白C(APC)是血管功能的重要调节因子,具有抗血栓形成和抗炎特性。人体研究表明,重组人APC(活化的重组人活化蛋白C)可调节内毒素诱导的低血压,然而,这种作用的机制尚不清楚。我们发现,APC可抑制强效血管活性肽肾上腺髓质素(ADM)的诱导,并可下调细胞培养中脂多糖(LPS)诱导的ADM信使核糖核酸(mRNA)和亚硝酸盐水平。这种作用依赖于蛋白酶激活受体1的信号传导。添加1400W(一种不可逆的诱导型一氧化氮合酶(iNOS)抑制剂)可抑制LPS诱导的ADM mRNA,表明ADM的诱导是由一氧化氮(NO)介导的。此外,在内毒素血症大鼠模型中,APC(100微克/千克,静脉注射)可预防LPS(10毫克/千克,静脉注射)诱导的低血压,并抑制ADM mRNA和蛋白表达。APC还抑制iNOS mRNA和蛋白水平,同时减少NO副产物(NOx)。我们还观察到APC处理后,粘附于血管内皮的iNOS阳性白细胞显著减少。此外,我们发现APC可抑制干扰素-γ(IFN-γ)的表达,IFN-γ是iNOS的强效激活剂。在一项关于LPS诱导低血压的人体研究中,APC降低了血浆ADM水平的上调,同时对低血压反应起到保护作用。总体而言,我们证明APC可阻断ADM的诱导,这可能由IFN-γ和iNOS介导,并提示了一种可能解释改善LPS诱导低血压的机制。此外,我们的数据为APC在调节血管对损伤反应中的作用提供了新的认识。